No Observed Skin Lesion Flares After Switching to Upadacitinib in Atopic Dermatitis
A post hoc analysis of the LEVEL UP and HEADS UP trials found no skin lesion flares in patients with moderate to severe atopic dermatitis who switched from dupilumab to upadacitinib (Rinvoq, AbbVie) after 16 weeks. The study, presented at the 2026 Fall Clinical Dermatology Conference, showed infrequent itch flares and suggested upadacitinib's superior efficacy over dupilumab (Dupixent, Regeneron and Sanofi).
How this was made
The 30-second read
Why it matters
First public disclosure of these specific flare‑rate results; supports upadacitinib efficacy but limited by small cohorts and no safety data.
Market read
Provides new efficacy data that could affect investor sentiment toward JAK inhibitors and biologics in dermatology, but limited immediate trading impact.
What to watch
Potential upcoming regulatory reviews of JAK inhibitors could offset any positive sentiment from the trial data.
Background
The article reports a post‑hoc analysis of two clinical trials (LEVEL UP and HEADS UP) presented at the 2026 Fall Clinical Dermatology Conference, comparing upadacitinib (AbbVie) to dupilumab (Regeneron/Sanofi) in atopic dermatitis patients who switched therapies.
Ticker impact
AbbVie’s upadacitinib showed no skin lesion flares after switching from dupilumab in a new post‑hoc analysis presented at a dermatology conference.
potential modest upside as the trial data supports efficacy
First public disclosure of favorable post‑hoc results; however, sample size is small and no safety data were released, limiting immediate price move.
Regeneron’s dupilumab was the comparator drug in the same analysis, which showed inferior flare control versus upadacitinib.
limited pressure as investors reassess dupilumab’s competitive position
Data are indirect and from a small post‑hoc study; market impact is likely muted.
Sanofi co‑markets dupilumab with Regeneron; the analysis highlighted dupilumab’s weaker flare control versus upadacitinib.
minimal impact, possible slight downside pressure
The study does not directly affect Sanofi’s earnings; any effect is peripheral.
Market effects
May influence investor perception of JAK inhibitors vs biologics in dermatology.
Limited to US biotech and pharma equities.
Low global relevance; primarily of interest to specialty drug investors.
Counterpoint
The small sample size and lack of safety data mean the results may be overstated; investors should wait for larger Phase 3 data.
Key entities
- CompanyAbbVie
Manufacturer of upadacitinib (Rinvoq).
- CompanyRegeneron Pharmaceuticals
Co‑developer of dupilumab (Dupixent).
- CompanySanofi
Partner in dupilumab development.
